Identification of factors associated with primary refractoriness to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma

被引：0

作者：

Manfredi, G. F. ^{[1
,2
]}

Fulgenzi, C. A. M. ^{[2
]}

D'Alessio, A. ^{[2
,3
]}

Celsa, C. ^{[2
,4
,5
]}

Stefanini, B. ^{[2
,6
]}

Cheon, J. ^{[7
]}

Ang, C. ^{[8
]}

Marron, T. U. ^{[8
]}

Saeed, A. ^{[9
]}

Wietharn, B. ^{[9
]}

Pressiani, T. ^{[10
]}

Pinter, M. ^{[11
]}

Scheiner, B. ^{[11
]}

Huang, Yi-Hsiang ^{[12
,13
]}

Phen, S. ^{[14
]}

Naqash, A. Rafeh ^{[15
]}

Piscaglia, F. ^{[6
]}

Lin, R. Po-Ting ^{[16
,17
]}

Lin, C. -yen ^{[16
,17
]}

Dalbeni, A. ^{[18
,19
]}

Vivaldi, C. ^{[20
,21
]}

Masi, G. ^{[20
,21
]}

Thimme, R. ^{[22
]}

Vogel, A. ^{[23
,24
,25
]}

Schonlein, M. ^{[26
]}

von Felden, J. ^{[27
]}

Schulze, K. ^{[27
]}

Wege, H. ^{[27
]}

Galle, P. R. ^{[28
]}

Kudo, M. ^{[29
]}

Rimassa, L. ^{[10
,30
]}

Singal, A. ^{[14
]}

Sharma, R. ^{[2
]}

Cortellini, A. ^{[1
,31
]}

Chon, H. Jae ^{[7
]}

Burlone, M. ^{[32
]}

Pirisi, M. ^{[1
,32
]}

Pinato, D. J. ^{[2
,3
]}

机构：

[1] Univ Piemonte Orientale, Dept Translat Med, Novara, Italy

[2] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Du Cane Rd, London, England

[3] Univ Piemonte Orientale, Div Oncol, Dept Translat Med, Novara, Italy

[4] Univ Palermo, Sect Gastroenterol & Hepatol, Dept Hlth Promot Mother & Child Care Internal Med, Palermo, Italy

[5] Univ Palermo, Dept Surg Oncol & Oral Sci Di Chir On S, Palermo, Italy

[6] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy

[7] CHA Univ, Dept Internal Med, CHA Bundang Med Ctr, Med Oncol, Seongnam, South Korea

[8] Tisch Canc Inst, Mt Sinai Hosp, Div Hematol Oncol, Dept Med, New York, NY USA

[9] Kansas Univ, Div Med Oncol, Dept Med, Canc Ctr, Kansas City, KS USA

[10] IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Humanitas Canc Ctr, Via A Manzoni 56, I-20089 Rozzano, Milan, Italy

[11] Med Univ Vienna, Div Gastroenterol & Hepatol, Dept Internal Med 3, Vienna, Austria

[12] Taipei Vet Gen Hosp, Div Gastroenterol & Hepatol, Dept Med, Taipei, Taiwan

[13] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Sch Med, Taipei, Taiwan

[14] Univ Texas Southwestern Med Ctr, Dept Internal Med, Dallas, TX USA

[15] Univ Oklahoma, Med Oncol, Stephenson Canc Ctr, TSET Phase 1 Program, Oklahoma City, OK USA

[16] Chang Gung Mem Hosp, Dept Gastroenterol & Hepatol, Linkou Med Ctr, Taoyuan, Taiwan

[17] Chang Gung Univ, Coll Med, Taoyuan, Taiwan

[18] Univ Verona, Dept Med, Gen Med C Unit, Verona, Italy

[19] Univ Verona, Liver Unit, Verona, Italy

[20] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy

[21] Azienda Osped Univ Pisana, Unit Med Oncol 2, Pisa, Italy

[22] Univ Freiburg, Freiburg Univ Med Ctr, Dept Med Gastroenterol Hepatol Endocrinol & Infec, Fac Med, Freiburg, Germany

[23] UHN, Toronto Gen Hosp, Toronto, ON M5G 2C4, Canada

[24] Princess Margaret Canc Ctr, Toronto, ON, Canada

[25] Hannover Med Sch, Hannover, Germany

[26] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Sect Pneumol, Hamburg, Germany

[27] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, Hamburg, Germany

[28] Univ Med Ctr Mainz, Dept Internal Med 1, Mainz, Germany

[29] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan

[30] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4, I-20072 Milan, Italy

[31] Fdn Policlin Univ Campus Biomed, Med Oncol, Rome, Italy

[32] AOU Maggiore Carita, Div Internal Med, Novara, Italy

来源：

DIGESTIVE AND LIVER DISEASE | 2024年 / 56卷

关键词：

D O I：

10.1016/j.dld.2024.01.012

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

OC-11

引用

页码：S8 / S9

页数：2

共 50 条

[41] Identification of a predictive phosphoproteomic signature of response to atezolizumab and bevacizumab (AB) in patients with advanced hepatocellular carcinoma (aHCC)
Sarker, Debashis
Borek, Weronika E.
Pedicona, Federico
Zen, Yoh
Christopher, Josie A.
Karampera, Christina
Campbell, Amy
Khorsandi, Shirin Elizabeth
Dowe, Thomas
Habarwaa, Marwo
Britton, David James
Heaton, Nigel
Cutillas, Pedro Rodriguez
Williamson, Andrew
Dokal, Arran David
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[42] Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Persano, M.
Rimini, M.
Tada, T.
Suda, G.
Shimose, S.
Kudo, M.
Yoo, C.
Cheon, J.
Finkelmeier, F.
Lim, H. Y.
Presa, J.
Masi, G.
Bergamo, F.
Iavarone, M. A.
Cabibbo, G.
Foschi, F. G.
Piscaglia, F.
Cascinu, S.
Scartozzi, M.
Gardini, A. Casadei
ANNALS OF ONCOLOGY, 2023, 34 : S1535 - S1535
[43] Impact of Atezolizumab plus Bevacizumab Therapy on Health-Related Quality of Life in Patients with Advanced Hepatocellular Carcinoma
Shomura, Masako
Okabe, Haruka
Sakakibara, Maya
Sato, Emi
Shiraishi, Koichi
Arase, Yoshitaka
Tsuruya, Kota
Mishima, Yusuke
Hirose, Shunji
Kagawa, Tatehiro
CANCERS, 2024, 16 (21)
[44] Tumor steatosis and glutamine synthetase expression in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy
Kurebayashi, Yutaka
Tsujikawa, Hanako
Sugimoto, Katsutoshi
Yunaiyama, Daisuke
Araki, Yoichi
Saito, Kazuhiro
Takahashi, Hiroshi
Kakegawa, Tatsuya
Wada, Takuya
Tomita, Yusuke
Abe, Masakazu
Yoshimasu, Yu
Takeuchi, Hirohito
Hirata, Taiki
Sakamaki, Kentaro
Kakimi, Kazuhiro
Nagao, Toshitaka
Itoi, Takao
Sakamoto, Michiie
HEPATOLOGY RESEARCH, 2023, 53 (10) : 1008 - 1020
[45] ANALYSIS OF FACTORS PREDICTING THE REAL-WORLD EFFICACY OF ATEZOLIZUMAB AND BEVACIZUMAB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
Ha, Chang Won
Paik, Yong-Han
Song, Byeong Geun
HEPATOLOGY, 2024, 80
[46] Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab
Kikuchi, Tatsuya
Takeuchi, Yasuto
Nouso, Kazuhiro
Kariyama, Kazuya
Kuwaki, Kenji
Toshimori, Junichi
Iwado, Shota
Moriya, Akio
Hagihara, Hiroaki
Takabatake, Hiroyuki
Tada, Toshifumi
Yasunaka, Tetsuya
Sakata, Masahiro
Sue, Masahiko
Miyake, Nozomi
Adachi, Takuya
Wada, Nozomu
Onishi, Hideki
Shiraha, Hidenori
Takaki, Akinobu
Otsuka, Motoyuki
LIVER INTERNATIONAL, 2024, 44 (06) : 1456 - 1463
[47] Analysis of Factors Predicting the Real-World Efficacy of Atezolizumab and Bevacizumab in Patients with Advanced Hepatocellular Carcinoma
Song, Byeong Geun
Goh, Myung Ji
Kang, Wonseok
Sinn, Dong Hyun
Gwak, Geum-Youn
Choi, Moon Seok
Lee, Joon Hyeok
Paik, Yong-Han
GUT AND LIVER, 2024, 18 (04) : 709 - 718
[48] IMPACT OF ATEZOLIZUMAB plus BEVACIZUMAB THERAPY ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
Shomura, Masako
Okabe, Haruka
Sato, Emi
Shiraishi, Koichi
Arase, Yoshitaka
Tsuruya, Kota
Mishima, Yusuke
Hirose, Shunji
Kagawa, Tatehiro
HEPATOLOGY, 2023, 78 : S1751 - S1752
[49] Long-term survival outcomes of atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma.
Chen, Ching-Tso
Feng, Yin-Hsun
Yen, Chia-Jui
Chen, San-Chi
Hsu, Chih-Hung
Shao, Yu-Yun
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
[50] Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab
Hsu, Chiun
Rimassa, Lorenza
Sun, Hui-Chuan
Vogel, Arndt
Kaseb, Ahmed O.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13

← 1 2 3 4 5 →